Welcome!

News Feed Item

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014

NEW YORK, March 18, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02051434/Diffuse-Large-B-Cell-Lymphoma-Global-Clinical-Trials-Review-H1-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Diffuse Large B-Cell Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diffuse Large B-Cell Lymphoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Introduction 6
Diffuse Large B-Cell Lymphoma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Diffuse Large B-Cell Lymphoma 25
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials 34
Prominent Drugs 36
Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma 37
Dec 09, 2013: Senesco Announces Results of Cohort 3 in SNS01-T Phase 1b/2a Trial 37
Aug 15, 2013: Seattle Genetics Announces Initiation of Phase 2 Trial of ADCETRIS in Combination with Current Standard of Care for Frontline Diffuse Large B-Cell Lymphoma 37
Jun 16, 2013: Pharmacyclics Announces Results Of Two Phase II Ibrutinib Studies In Patients With Mantle Cell Lymphoma Or Diffuse Large B-Cell Lymphoma 38
Jun 10, 2013: Immunomedics's 90Y-Epratuzumab Study Shows Improvement Of Therapy Results Following R-CHOP In Patients With Diffuse Large B-Cell Lymphoma 39
May 10, 2013: Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint In Diffuse Large B-Cell Lymphoma 40
Clinical Trial Profiles 41
Clinical Trial Overview of Top Companies 41
F. Hoffmann-La Roche Ltd. 41
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 41
Celgene Corporation 44
Clinical Trial Overview of Celgene Corporation 44
Amgen Inc. 46
Clinical Trial Overview of Amgen Inc. 46
Novartis AG 48
Clinical Trial Overview of Novartis AG 48
Takeda Pharmaceutical Company Limited 50
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 50
Pharmacyclics, Inc. 51
Clinical Trial Overview of Pharmacyclics, Inc. 51
GlaxoSmithKline plc 52
Clinical Trial Overview of GlaxoSmithKline plc 52
Bayer AG 53
Clinical Trial Overview of Bayer AG 53
AstraZeneca PLC 54
Clinical Trial Overview of AstraZeneca PLC 54
Immunomedics, Inc. 55
Clinical Trial Overview of Immunomedics, Inc. 55
Clinical Trial Overview of Top Institutes / Government 56
National Cancer Institute 56
Clinical Trial Overview of National Cancer Institute 56
Fred Hutchinson Cancer Research Center 61
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 61
Groupe d'Etudes de Lymphomes de L'Adulte 64
Clinical Trial Overview of Groupe d'Etudes de Lymphomes de L'Adulte 64
Mayo Clinic 65
Clinical Trial Overview of Mayo Clinic 65
The University of Texas M. D. Anderson Cancer Center 66
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 66
FUDAN University 67
Clinical Trial Overview of FUDAN University 67
Memorial Sloan Kettering Cancer Center 68
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 68
The Lymphoma Academic Research Organisation 69
Clinical Trial Overview of The Lymphoma Academic Research Organisation 69
Massachusetts General Hospital 70
Clinical Trial Overview of Massachusetts General Hospital 70
Stanford University 71
Clinical Trial Overview of Stanford University 71
Five Key Clinical Profiles 72
Appendix 164
Abbreviations 164
Definitions 164
Research Methodology 165
Secondary Research 165
About GlobalData 166
Contact Us 166
Disclaimer 166
Source 167

List of Tables

Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region, 2014* 7
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 32
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 41
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014* 44
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 46
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 48
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 50
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacyclics, Inc., 2014* 51
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 52
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 53
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 54
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Immunomedics, Inc., 2014* 55
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 56
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014* 61
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Groupe d'Etudes de Lymphomes de L'Adulte, 2014* 64
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014* 65
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 66
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2014* 67
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 68
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The Lymphoma Academic Research Organisation, 2014* 69
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 70
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 71

List of Figures
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 32
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
GlobalData Methodology 165

To order this report: Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02051434/Diffuse-Large-B-Cell-Lymphoma-Global-Clinical-Trials-Review-H1-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Cloud-based disaster recovery is critical to any production environment and is a high priority for many enterprise organizations today. Nearly 40% of organizations have had to execute their BCDR plan due to a service disruption in the past two years. Zerto on IBM Cloud offer VMware and Microsoft customers simple, automated recovery of on-premise VMware and Microsoft workloads to IBM Cloud data centers.
In his session at @ThingsExpo, Greg Gorman is the Director, IoT Developer Ecosystem, Watson IoT, will provide a short tutorial on Node-RED, a Node.js-based programming tool for wiring together hardware devices, APIs and online services in new and interesting ways. It provides a browser-based editor that makes it easy to wire together flows using a wide range of nodes in the palette that can be deployed to its runtime in a single-click. There is a large library of contributed nodes that help so...
SYS-CON Events announced today that mruby Forum will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. mruby is the lightweight implementation of the Ruby language. We introduce mruby and the mruby IoT framework that enhances development productivity. For more information, visit http://forum.mruby.org/.
SYS-CON Events announced today that N3N will exhibit at SYS-CON's @ThingsExpo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. N3N’s solutions increase the effectiveness of operations and control centers, increase the value of IoT investments, and facilitate real-time operational decision making. N3N enables operations teams with a four dimensional digital “big board” that consolidates real-time live video feeds alongside IoT sensor data a...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...
SYS-CON Events announced today that SourceForge has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. SourceForge is the largest, most trusted destination for Open Source Software development, collaboration, discovery and download on the web serving over 32 million viewers, 150 million downloads and over 460,000 active development projects each and every month.
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
Today most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes significant work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reducti...
SYS-CON Events announced today that Daiya Industry will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Daiya Industry specializes in orthotic support systems and assistive devices with pneumatic artificial muscles in order to contribute to an extended healthy life expectancy. For more information, please visit https://www.daiyak...
SYS-CON Events announced today that Nihon Micron will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Nihon Micron Co., Ltd. strives for technological innovation to establish high-density, high-precision processing technology for providing printed circuit board and metal mount RFID tags used for communication devices. For more inf...
SYS-CON Events announced today that Massive Networks, that helps your business operate seamlessly with fast, reliable, and secure internet and network solutions, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. As a premier telecommunications provider, Massive Networks is headquartered out of Louisville, Colorado. With years of experience under their belt, their team of...
SYS-CON Events announced today that Suzuki Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Suzuki Inc. is a semiconductor-related business, including sales of consuming parts, parts repair, and maintenance for semiconductor manufacturing machines, etc. It is also a health care business providing experimental research for...
"Our strategy is to focus on the hyperscale providers - AWS, Azure, and Google. Over the last year we saw that a lot of developers need to learn how to do their job in the cloud and we see this DevOps movement that we are catering to with our content," stated Alessandro Fasan, Head of Global Sales at Cloud Academy, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...